|
|
|
| home > white papers > Data Technology as a Catalyst for Growth in the Life Sciences - AIGENPULSE |
|
|
 WHITE PAPERS |
|
|
AIGENPULSE
|
|
Data Technology as a Catalyst for Growth in the Life Sciences
|
|
The life sciences industry is changing at a rapid pace. The need to develop the next blockbuster is pushing current technologies and methodologies to the limit. Scientific advancement over the last decades was embossed with giant leaps in knowledge, however, the new reality is that smaller incremental gains need to be carved out with ever increasing investments. In order to survive, progress and prosper in this new reality, a holistic approach to getting the most of research data is crucial. In fact, it will likely be the difference of being in existence in 5-10 years or not. For those bold enough to step into an area they are unfamiliar with, huge rewards are waiting.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Non-invasive SONOFLOW | Flow Sensors and SONOFLOW | C³ Software: The user-friendly smart sensoring package for application in laboratory 4.0, R&D, and single-use production environments
With the influence of digitization and increasing needs for process monitoring, laboratory, R&D, and single-use production environments are changing rapidly. Networked laboratory devices with smart functions, automation concepts, and efficient interface solutions have altered laboratory workflows and stand for the new era of Lab 4.0. Therefore, a rising tide of the continuous availability of data requires an easy data handling and secure data logging.
More info >> |
|
 |
White Papers |
 |
|
Case Study: Cmed’s Mobile Data Management Solution
Cmed Clinical Services
The trial presented to Cmed was a randomized, double blinded, placebo
and active controlled study to evaluate the cardiac safety of multiple
doses of [study drug] in health volunteers.
The pharmaceutical
company, who were into the second year of development of a potential
blockbuster compound for the treatment of chronic myelogenous leukaemia
(CML), were requested by the FDA to design a trial to provide
information on the cardiac safety of different dose levels of the study
drug in healthy adult volunteers. The primary objective of the study was
specifically to find the maximum tolerated dose before QTc levels
became unsafe. All development of the compound was put on hold until the
results of this study were submitted to the FDA and approval granted
for the compound to progress into full development.
More info >> |
|
 |
Industry Events |
 |
SMi Presents the 4th Annual: Highly Potent Active Pharmaceutical Ingredients (HPAPI)
11-13 May 2020, Copthorne Tara Hotel, London, UK
SMi is delighted to announce its 4th Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 11th – 12th May 2020.
HPAPI 2020 conference focuses on the growing landscape driven by the demand for highly potent drugs in oncology, diabetes and autoimmune disease treatment. This event will address the biggest challenges the industry is facing with regards to determining toxicology limits, assessing hazards, implementing risk procures, translating risk assessment into facility engineering, preventing and dealing with cross-contamination and adhering to GMP regulatory guidelines.
More info >> |
|
|
|
